Bmc health services research cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

HIGHLIGHTS

• who: Ting Zhou et al. from the Similarly, the oral multiple receptor tyrosine kinase inhibitor lenvatinib was approved for advanced HCC by the NMPA in The phase III clinical trial REFLECT showed that lenvatinib is non-inferior to sorafenib in terms of improving patient overall survival (OS) [9]. Although sintilimab plus bevacizumab biosimilar therapy and lenvatinib have shown good efficacy in clinical trials and are recommended by Chinese guideline[5], a comparison of the cost- and clinical-effectiveness of these regimens has not yet been undertaken in a Chinese setting. Therefore, this study aimed to evaluate the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.